25Jan/14

A pill may replace chemotherapy in treating leukemia – Authint Mail


Financial Express

A pill may replace chemotherapy in treating leukemia
Authint Mail
A team of researchers from 19 medical centres in five countries have found that use of a combination of two targeted drugs – idelalsib and rituximab – can make the use of debilitating chemotherapy redundant in the treatment of CLL, a cancer of the
Drug Combo ‘Melts Away’ LeukemiaDrug Discovery & Development

all 27 news articles »

24Jan/14

Halozyme Therapeutics recommended for European Commission approval – San Diego Source (subscription)

Halozyme Therapeutics recommended for European Commission approval
San Diego Source (subscription)
The treatment is Roche’s subcutaneous formulation of MabThera (rituximab) using Halozyme’s recombinant human hyaluronidase (rHuPH20). “This subcutaneous formulation of MabThera, pending approval in the EU, provides a new route of administration 
Halozyme Announces Positive Opinion From CHMP For European Approval Of PR Newswire (press release)

all 14 news articles »

24Jan/14

A pill may replace chemotherapy in treating leukemia – Daijiworld.com


Financial Express

A pill may replace chemotherapy in treating leukemia
Daijiworld.com
A team of researchers from 19 medical centres in five countries have found that use of a combination of two targeted drugs – idelalsib and rituximab – can make the use of debilitating chemotherapy redundant in the treatment of CLL, a cancer of the
Pill ‘melts away’ common form of leukaemiaBusiness Standard
New pill can ‘melt away’ leukemia without chemotherapyTruthDive

all 27 news articles »

24Jan/14

NICE set to extend MabThera recommendation – PMLiVE

NICE set to extend MabThera recommendation
PMLiVE
Final draft guidance from the National Institute for Health and Care Excellence (NICE) recommends MabThera (rituximab) be available for use on the NHS to treat severe forms of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).
UK’s NICE gives green light to Roche’s MabThera for GPA and MPAThe Pharma Letter

all 3 news articles »

24Jan/14

Use of twice-daily pill could turn deadly blood cancer into highly treatable … – News-Medical.net


Drug Discovery & Development

Use of twice-daily pill could turn deadly blood cancer into highly treatable
News-Medical.net
They found that those who received the combination of idelalsib and rituximab went longer without their disease worsening than those who received only rituximab, which has been the standard of care. Six months into the study, cancers in 93 percent of 
New pill can ‘melt away’ leukemia without chemotherapyZee News
A pill may replace chemotherapy in treating leukemiaBusiness Standard

all 18 news articles »